For as many execution issues as Boston Scientific (NYSE: BSX )
has had over the years, current management deserves credit for the
extent to which they have changed both the reality of the business and
Wall Street's perception of it. The company is still behind large rivals
in key growth areas like transcathether heart valves and renal
denervation, but it is no longer a notable laggard in terms of reported
growth.
The only real downside that I see to the story is that expectations
have moved to a point where it seems like the Street is giving the
company a lot of benefit of the doubt with respect to its execution in
2014. The next 12 months should see meaningful progress across multiple
product lines, but it's hard to argue that the shares are notably
undervalued after the big move over the past year.
Please read the full article here:
http://www.fool.com/investing/general/2013/10/28/wall-street-fully-on-board-with-boston-scientific.aspx
No comments:
Post a Comment